Emtricitabine indications and usage: Difference between revisions

Jump to navigation Jump to search
Line 6: Line 6:


EMTRIVA® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
EMTRIVA® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.


Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection.
Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection.


EMTRIVA should not be coadministered with ATRIPLA®, COMPLERA®, STRIBILD™, TRUVADA®, or lamivudine-containing products.
EMTRIVA should not be coadministered with ATRIPLA®, COMPLERA®, STRIBILD™, TRUVADA®, or lamivudine-containing products.

Revision as of 02:59, 2 January 2014

Emtricitabine
EMTRIVA® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Clinical Studies
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Indications and Usage

EMTRIVA® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection.

EMTRIVA should not be coadministered with ATRIPLA®, COMPLERA®, STRIBILD™, TRUVADA®, or lamivudine-containing products. In treatment-experienced patients, the use of EMTRIVA should be guided by laboratory testing and treatment history.[1]

References

  1. "EMTRIVA (EMTRICITABINE) CAPSULE EMTRIVA (EMTRICITABINE) SOLUTION [GILEAD SCIENCES, INC.]".

Adapted from the FDA Package Insert.